20 results
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
14 May 24
InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
4:12pm
contributions, and leadership during her tenure with InMed and wish her all the best in her retirement. We congratulate her on a tremendous career in the biotech
424B3
INM
InMed Pharmaceuticals Inc
19 Oct 22
Prospectus supplement
6:10am
with a public company in the United States and a public company in Australia. Dr. Garner brings additional medical affairs experience from his tenure
8-K
neqwf9lc874b5agr
18 May 22
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
1:34pm
8-K
EX-99.1
cxswtj4fq8xtv4q1
18 May 22
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
1:34pm
DEF 14A
eo5ddimwp92t
28 Oct 21
Definitive proxy
3:07pm
424B3
jxz6ar85pg1cliqb
22 Jul 21
Prospectus supplement
10:27am
424B3
u7dzx4v
16 Mar 21
Prospectus supplement
12:00am
424B4
ixo6lqn
13 Nov 20
Prospectus supplement with pricing info
8:52pm
S-1
x838ckulgnryv 3cn5
19 Jun 20
IPO registration
4:59pm
DRS/A
gypuqapg ngu3
27 May 20
Draft registration statement (amended)
12:00am
DRS
rn8lpskx tj4dhv
13 Apr 20
Draft registration statement
12:00am
- Prev
- 1
- Next